Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity

Journal of Molecular Recognition

Volumn 25, Issue 1, 2012, Pages 57-67

  Gunzburg, Menachem J ^a   Ambaye, Nigus D ^a   Del Borgo, Mark P ^a   Pero, Stephanie C ^b   Krag, David N ^b   Wilce, Matthew C J ^a   Wilce, Jacqueline A ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Grb7; Non phosphorylated cyclic peptide; Peptide inhibitor; SH2 domain; Surface Plasmon resonance

Indexed keywords

CYCLOPEPTIDE; G7 18NATE; G7-18NATE; GRB14 PROTEIN, HUMAN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; PHOSPHATE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SODIUM DIHYDROGEN PHOSPHATE;

AMINO ACID SEQUENCE; ARTICLE; BREAST TUMOR; CELL ADHESION; CELL MOTION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SRC HOMOLOGY DOMAIN; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GRB10 ADAPTOR PROTEIN; GRB2 ADAPTOR PROTEIN; GRB7 ADAPTOR PROTEIN; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PHOSPHATES; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SRC HOMOLOGY DOMAINS; SURFACE PLASMON RESONANCE;

EID: 84855296314     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2148     Document Type: Article

References (48)

1. Ambaye ND, Gunzburg MJ, Lim RC, Price JT, Wilce MC, Wilce JA,. 2011a. Benzopyrazine derivatives: a novel class of growth factor receptor bound protein 7 antagonists. Bioorg. Med. Chem. 19 (1): 693-701.
2. Ambaye ND, Lim RC, Clayton DJ, Gunzburg MJ, Price JT, Pero SC, Krag DN, Wilce MC, Aguilar MI, Perlmutter P, Wilce JA,. 2011b. Uptake of a cell permeable G7-18NATE construct into cells and binding with the Grb7-SH2 domain. Biopolymers 96 (2): 181-188.
3. Ambaye ND, Pero SC, Gunzburg MJ, Yap MY, Clayton DJ, Del Borgo MP, Perlmutter P, Aguilar MI, Shukla GS, Elena Peletskaya E, Cookson MM, Krag DN, Wilce MC, Wilce JA,. 2011c. Structural basis of binding by cyclic non-phosphorylated peptide antagonists of Grb7 implicated in breast cancer progression. J. Mol. Biol. 412 (3): 397-411.
4. Bai T, Luoh SW,. 2008. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis 29 (3): 473-479. (Pubitemid 351404862)
5. Bradshaw JM, Waksman G,. 1998. Calorimetric investigation of proton linkage by monitoring both the enthalpy and association constant of binding: application to the interaction of the Src SH2 domain with a high-affinity tyrosyl phosphopeptide. Biochemistry 37 (44): 15400-15407. (Pubitemid 28516001)
6. Burke TR,. 2006. Development of Grb2 SH2 domain signaling antagonists: a potential new class of antiproliferative agents. Int. J. Pept. Res. Ther. 12 (1): 33-48.
7. Chu PY, Huang LY, Hsu CH, Liang CC, Guan JL, Hung TH, Shen TL,. 2009. Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis. J. Biol. Chem. 284 (30): 20215-20226.
8. Daly RJ,. 1998. The Grb7 family of signalling proteins. Cell. Signal. 10 (9): 613-618. (Pubitemid 28448461)
9. Daly RJ, Sanderson GM, Janes PW, Sutherland RL,. 1996. Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J. Biol. Chem. 271 (21): 12502-12510. (Pubitemid 26160922)
10. Eck MJ, Shoelson SE, Harrison SC,. 1993. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature 362 (6415): 87-91. (Pubitemid 23087298)
11. Erecinska M, Stubbs M, Miyata Y, Ditre CM,. 1977. Regulation of cellular metabolism by intracellular phosphate. Biochim. Biophys. Acta 462 (1): 20-35. (Pubitemid 8232604)
12. Gunzburg MJ, Ambaye ND, Hertzog JT, Del Borgo MP, Pero SC, Krag DN, Wilce MC, Aguilar MI, Perlmutter P, Wilce JA,. 2010. Use of SPR to Study the Interaction of G7-18NATE Peptide with the Grb7-SH2 Domain. Int. J. Pept. Res. Ther. 16: 177-184.
13. Han DC, Guan JL,. 1999. Association of focal adhesion kinase with Grb7 and its role in cell migration. J. Biol. Chem. 274 (34): 24425-24430.
14. Holt LJ, Siddle K,. 2005. Grb10 and Grb14: enigmatic regulators of insulin action-and more? Biochem. J. 388 (Pt 2): 393-406. (Pubitemid 40839916)
15. Itoh S, Taketomi A, Tanaka S, Harimoto N, Yamashita Y, Aishima S, Maeda T, Shirabe K, Shimada M, Maehara Y,. 2007. Role of growth factor receptor bound protein 7 in hepatocellular carcinoma. Mol. Cancer Res. 5 (7): 667-673. (Pubitemid 47105485)
16. Ivancic M, Daly RJ, Lyons BA,. 2003. Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2. J. Biomol. NMR 27 (3): 205-219. (Pubitemid 37185122)
17. Janes PW, Lackmann M, Church WB, Sanderson GM, Sutherland RL, Daly RJ,. 1997. Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. J. Biol. Chem. 272 (13): 8490-8497. (Pubitemid 27147812)
18. Kao J, Pollack JR,. 2006. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45 (8): 761-769.
19. Kasembeli MM, Xu X, Tweardy DJ,. 2009. SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front. Biosci. 14: 1010-1022.
20. Kimber MS, Nachman J, Cunningham AM, Gish GD, Pawson T, Pai EF,. 2000. Structural basis for specificity switching of the Src SH2 domain. Mol. Cell 5 (6): 1043-1049.
21. Kishi T, Sasaki H, Akiyama N, Ishizuka T, Sakamoto H, Aizawa S, Sugimura T, Terada M,. 1997. Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer. Biochem. Biophys. Res. Commun. 232 (1): 5-9. (Pubitemid 27211909)
22. Lange G, Lesuisse D, Deprez P, Schoot B, Loenze P, Benard D, Marquette JP, Broto P, Sarubbi E, Mandine E,. 2003. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J. Med. Chem. 46 (24): 5184-5195. (Pubitemid 37414188)
23. Liu BA, Jablonowski K, Raina M, Arce M, Pawson T, Nash PD,. 2006. The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol. Cell 22 (6): 851-868.
24. Machida K, Mayer BJ,. 2005. The SH2 domain: versatile signaling module and pharmaceutical target. Biochim. Biophys. Acta 1747 (1): 1-25. (Pubitemid 40170450)
25. Manser J, Roonprapunt C, Margolis B,. 1997. C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development. Dev. Biol. 184 (1): 150-164. (Pubitemid 27225705)
26. Nadler Y, Gonzalez AM, Camp RL, Rimm DL, Kluger HM, Kluger Y,. 2010. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann. Oncol. 21 (3): 466-473.
27. Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A,. 2010. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One 5 (2): e9024.
28. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T,. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4 (11): 2411-2423.
29. Pascal SM, Yamazaki T, Singer AU, Kay LE, Forman-Kay JD,. 1995. Structural and dynamic characterization of the phosphotyrosine binding region of a Src homology 2 domain-phosphopeptide complex by NMR relaxation, proton exchange, and chemical shift approaches. Biochemistry 34 (36): 11353-11362.
30. Pawson T,. 2004. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116 (2): 191-203. (Pubitemid 38167312)
31. Pawson T, Gish GD, PNash P,. 2005. The SH2 domain: a prototype for protein interaction modules. In modular protein domains, Cesareni G, Gimona M, Sudol M, Yaffe M, (eds). Weinheim: Wiley-VCH. 5-36.
32. Pero SC, Daly RJ, Krag DN,. 2003. Grb7-based molecular therapeutics in cancer. Expert Rev. Mol. Med. 5 (14): 1-11.
33. Pero SC, Oligino L, Daly RJ, Soden AL, Liu C, Roller PP, Li P, Krag DN,. 2002. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J. Biol. Chem. 277 (14): 11918-11926. (Pubitemid 34952750)
34. Pero SC, Shukla GS, Cookson MM, Flemer S, Jr., Krag DN,. 2007. Combination treatment with Grb7 peptide and doxorubicin or trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br. J. Cancer 96 (10): 1520-1525. (Pubitemid 46762945)
35. Perozzo R, Folkers G, Scapozza L,. 2004. Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J. Recept. Signal Transduct. Res. 24 (1-2): 1-52. (Pubitemid 39011288)
36. Pias S, Peterson TA, Johnson DL, Lyons BA,. 2010. The intertwining of structure and function: proposed helix-swapping of the SH2 domain of Grb7, a regulatory protein implicated in cancer progression and inflammation. Crit. Rev. Immunol. 30 (3): 299-304.
37. Porter CJ, Wilce JA,. 2007. NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein. Biopolymers 88 (2): 174-181. (Pubitemid 46657983)
38. Porter CJ, Matthews JM, Mackay JP, Pursglove SE, Schmidberger JW, Leedman PJ, Pero SC, Krag DN, Wilce MC, Wilce JA,. 2007. Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation. BMC Struct. Biol. 7: 58.
39. Porter CJ, Wilce MC, Mackay JP, Leedman P, Wilce JA,. 2005. Grb7-SH2 domain dimerisation is affected by a single point mutation. Eur. Biophys. J. 34 (5): 454-460. (Pubitemid 41040169)
40. Sambrook J, Fritsch EF, Maniatis T,. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press: Planview, NY, USA; B21.
41. Shen TL, Guan JL,. 2001. Differential regulation of cell migration and cell cycle progression by FAK complexes with Src, PI3K, Grb7 and Grb2 in focal contacts. FEBS Lett. 499 (1-2): 176-181.
42. Shen TL, Guan JL,. 2004. Grb7 in intracellular signaling and its role in cell regulation. Front. Biosci. 9: 192-200.
43. Spuches AM, Argiros HJ, Lee KH, Haas LL, Pero SC, Krag DN, Roller PP, Wilcox DE, Lyons BA,. 2007. Calorimetric investigation of phosphorylated and non-phosphorylated peptide ligand binding to the human Grb7-SH2 domain. J. Mol. Recognit. 20 (4): 245-252. (Pubitemid 47523031)
44. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B,. 1994. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 13 (6): 1331-1340. (Pubitemid 24090214)
45. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K,. 1997. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res. 57 (1): 28-31. (Pubitemid 27020323)
46. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S,. 2006. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J. Natl. Cancer Inst. 98 (7): 491-498.
47. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J,. 1993. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72 (5): 779-790. (Pubitemid 23093885)
48. Ward WH, Holdgate GA,. 2001. Isothermal titration calorimetry in drug discovery. Prog. Med. Chem. 38: 309-376.